Edgestream Partners L.P. Invests $5.13 Million in Ionis Pharmaceuticals, Inc. $IONS

Edgestream Partners L.P. acquired a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the first quarter, Holdings Channel.com reports. The firm acquired 68,369 shares of the company’s stock, valued at approximately $5,134,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brown Brothers Harriman & Co. acquired a new stake in Ionis Pharmaceuticals during the fourth quarter worth approximately $27,000. Cassaday & Co Wealth Management LLC acquired a new position in Ionis Pharmaceuticals in the first quarter valued at approximately $30,000. Quarry LP acquired a new position in Ionis Pharmaceuticals in the third quarter valued at approximately $38,000. Johnson Financial Group Inc. bought a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $44,000. Finally, Laurel Wealth Advisors LLC bought a new position in shares of Ionis Pharmaceuticals during the 4th quarter worth approximately $47,000. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Trading Down 2.8%

Shares of Ionis Pharmaceuticals stock opened at $51.77 on Friday. The stock has a market capitalization of $8.56 billion, a PE ratio of -14.96 and a beta of 0.36. Ionis Pharmaceuticals, Inc. has a 52 week low of $40.03 and a 52 week high of $86.74. The stock has a 50 day moving average price of $69.55 and a two-hundred day moving average price of $74.57. The company has a debt-to-equity ratio of 3.07, a quick ratio of 4.09 and a current ratio of 7.89.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.29. Ionis Pharmaceuticals had a negative return on equity of 111.08% and a negative net margin of 64.76%.The company had revenue of $246.09 million for the quarter, compared to analyst estimates of $195.56 million. During the same period in the prior year, the firm earned ($0.93) earnings per share. Ionis Pharmaceuticals’s revenue for the quarter was up 86.4% on a year-over-year basis. As a group, equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.69 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, Director Allene M. Diaz sold 10,111 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $85.42, for a total transaction of $863,681.62. Following the completion of the sale, the director owned 3,811 shares in the company, valued at approximately $325,535.62. The trade was a 72.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael R. Hayden purchased 5,000 shares of the firm’s stock in a transaction on Friday, July 31st. The shares were acquired at an average price of $51.60 per share, with a total value of $258,000.00. Following the purchase, the director directly owned 24,000 shares in the company, valued at $1,238,400. This represents a 26.32% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold a total of 233,163 shares of company stock worth $18,316,551 in the last quarter. Insiders own 1.81% of the company’s stock.

Analyst Ratings Changes

IONS has been the subject of several research analyst reports. Canaccord Genuity Group lowered their price objective on shares of Ionis Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research note on Friday, July 17th. Raymond James Financial set a $87.00 price target on shares of Ionis Pharmaceuticals in a report on Thursday, July 9th. Oppenheimer reaffirmed an “outperform” rating and issued a $111.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, April 30th. Finally, Leerink Partners lifted their price target on shares of Ionis Pharmaceuticals from $122.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Eighteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $94.85.

Key Headlines Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Ionis beat Wall Street’s second-quarter revenue and earnings expectations, helped by commercial growth despite difficult year-over-year comparisons. Management also reaffirmed its 2026 outlook, supporting confidence in the company’s operating trajectory. Zacks Q2 earnings report
• Positive Sentiment: Director Michael R. Hayden bought 15,000 shares for approximately $800,700 on July 30 and another 5,000 shares for $258,000 on July 31. The purchases materially increased his ownership and may be viewed as a signal of confidence in Ionis’s valuation and prospects. SEC insider-trading filing
• Neutral Sentiment: Wells Fargo lowered its price target from $100 to $95 while maintaining an “overweight” rating. The reduced target reflects more cautious valuation expectations, but the rating remains bullish. Benzinga analyst report
• Neutral Sentiment: HC Wainwright cut its target from $125 to $115 but retained a “buy” rating, similarly indicating lower near-term valuation expectations while maintaining a positive view of the stock. StreetInsider analyst report
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Ionis investors. Although the announcement does not establish wrongdoing, it adds legal and reputational uncertainty and may weigh on sentiment. Pomerantz investor alert

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.